Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae)

Creator(s)

Eric Rhoden, Centers for Disease Control and Prevention
W. Allan Nix, Centers for Disease Control and Prevention
William C. Weldon, Centers for Disease Control and Prevention
Rangaraj Selvarangan, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

1-2018

Identifier

DOI: 10.1016/j.antiviral.2017.11.011

Abstract

© 2017 Parechovirus A3 (Par-A3, formerly human parechovirus 3) is an emerging viral infection of the central nervous system in children. We used an automated, homogeneous, cell based assay to identify itraconazole and posaconazole as inhibitors of Par-A3, with antiviral activity below concentrations clinically attainable in pediatric patients. Currently, there is no approved antiviral treatment for Par-A3 infection, despite numerous reports of serious Par-A3 disease in neonates and infants.

Journal Title

Antiviral Research

Volume

149

First Page

75

Last Page

77

Recommended Citation

Rhoden E, Nix WA, Weldon WC, Selvarangan R. Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae). Antiviral Res. 2018;149:75-77. doi:10.1016/j.antiviral.2017.11.011